相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Efficacy and safety of TMC278 in antiretroviral-naive HIV-1 patients: week 96 results of a phase IIb randomized trial
Anton L. Pozniak et al.
AIDS (2010)
Pharmacokinetics and Pharmacodynamics of GS-9350: A Novel Pharmacokinetic Enhancer Without Anti-HIV Activity
A. A. Mathias et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2010)
Efficacy and Safety of Maraviroc Versus Efavirenz, Both With Zidovudine/Lamivudine: 96-Week Results From the MERIT Study
Juan Sierra-Madero et al.
HIV CLINICAL TRIALS (2010)
Pharmacokinetics and Bioavailability of an Integrase and Novel Pharmacoenhancer-Containing Single-Tablet Fixed-Dose Combination Regimen for the Treatment of HIV
Polina German et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2010)
Antiretroviral Treatment of Adult HIV Infection 2010 Recommendations of the International AIDS Society-USA Panel
Melanie A. Thompson et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2010)
Activity of Elvitegravir, a Once-Daily Integrase Inhibitor, against Resistant HIV Type 1: Results of a Phase 2, Randomized, Controlled, Dose-Ranging Clinical Trial
Andrew R. Zolopa et al.
JOURNAL OF INFECTIOUS DISEASES (2010)
Dose-Response of Ritonavir on Hepatic CYP3A Activity and Elvitegravir Oral Exposure
A. A. Mathias et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2009)
Sustained Antiretroviral Effect of Raltegravir After 96 Weeks of Combination Therapy in Treatment-Naive Patients With HIV-1 Infection
Martin Markowitz et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2009)
Efavirenz: a decade of clinical experience in the treatment of HIV
Franco Maggiolo
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2009)
Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial
Jeffrey L. Lennox et al.
LANCET (2009)
Increased regimen durability in the era of once-daily fixed-dose combination antiretroviral therapy
James H. Willig et al.
AIDS (2008)
British HIV Association guidelines for the treatment of HIV-1-infected adults with antiretroviral therapy 2008
B. G. Gazzard
HIV MEDICINE (2008)
Rapid and durable Antiretroviral effect of the HIV-1 integrase inhibitor raltegravir as part of combination therapy in treatment-naive patients with HIV-1 infection - Results of a 48-week controlled study
Martin Markowitz et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2007)
Efavirenz and chronic neuropsychiatric symptoms: a cross-sectional case control study
T. A. Rihs et al.
HIV MEDICINE (2006)
Antiviral activity, pharmacokinetics, and dose response of the HIV-1 integrase inhibitor GS-9137 (JTK-303) in treatment-naive and treatment-experienced patients
Edwin DeJesus et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2006)
Neuropsychiatric complications of antiretroviral therapy
Michelle S. Cespedes et al.
DRUG SAFETY (2006)
Impact of efavirenz on neuropsychological performance and symptoms in HIV-infected individuals
DB Clifford et al.
ANNALS OF INTERNAL MEDICINE (2005)
The effect of low-dose ritonavir monotherapy on fasting serum lipid concentrations
SD Shafran et al.
HIV MEDICINE (2005)
Long-term neuropsychiatric disorders on efavirenz-based approaches:: Quality of life, psychologic issues, and adherence
CR Fumaz et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2005)
Factors affecting adherence to antiretroviral therapy
MA Chesney
CLINICAL INFECTIOUS DISEASES (2000)
分享论文
